accès au médicaments

Oxfam today praised the Medicine Patent Pool (MPP) for securing the first licenses for HIV medicines with the pharmaceutical company Gilead, a move that will boost the affordability and eff

Vaccines have contributed to some of the greatest public health successes of the past century, averting 2.5 million child deaths every year and millions more bouts of illness and dis

As the next round of Anti-Counterfeiting Trade Agreement negotiations get underway this week, Oxfam has called on the negotiating parties to ensure the Agreement does not erect new barriers that prevent generic medicines from reaching poor countries.

Access to medicines poses a critical challenge in developing countries: prices are high, and new or adapted medicines and vaccines to address diseases of the developing world are lacking.

Access to medicines is a major challenge for people in developing countries. With the right medicines, diseases such as HIV and AIDS, tuberculosis (TB), and malaria are treatable.

17 Feb – Pharmaceutical giant GlaxoSmithKline should be congratulated for breaking industry ranks and taking a major step toward helping poor people in developing countries to get better access to medicines, says international agency Oxfam. However GSK’s initiative this week is just the beginning.

Rich country donors and the World Bank are wasting money and risking lives by continuing to push unproven and discredited private healthcare programs in poor countries. Oxfam’s warning comes in a new report ‘Blind Optimism: Challenging the myths about private health care in poor countries’.